Equinix heads into the final days of August with bears in full retreat — yet the stock itself is slipping, creating an unusual gap between improving sentiment and near-term price action.
Short sellers have stepped back sharply. Positions fell 16% over the week to just 1.7% of the free float, the lowest reading in over a month and well below the levels that defined most of July. At this level, short interest is simply not a meaningful pressure on the stock. The lending market confirms as much: borrow availability is extraordinarily wide, with over 88 million shares available against roughly 1.6 million shorted. Cost to borrow remains negligible at 0.36%, even after drifting about 9% higher on the week and around 32% higher over the past month — in absolute terms, this is still a deeply easy name to borrow. The ORTEX short score has also eased, falling from 32.5 in mid-August to 31.3 by August 27, reinforcing the picture of declining bear conviction.
Options positioning is less bullish than the short data, though it has improved materially this week. The put/call ratio has dropped to 2.36, almost 1.6 standard deviations below its 20-day average of 2.73. For context, that average itself is well above 1.0 — EQIX perpetually carries a heavy put skew given its REIT structure and rate sensitivity. What is notable is the direction: the PCR was above 3.3 as recently as August 21 and has been compressing steadily through the week, suggesting options traders are unwinding defensive hedges into the price dip rather than adding them.
The Street remains firmly in the bull camp, and recent analyst activity has been almost uniformly constructive. Evercore ISI lifted its target to $1,270 on August 18. RBC raised to $1,225 in early August after taking the prior target from $1,125 — a move that signals genuine conviction rather than incremental trimming. A cluster of Buy-rated firms including UBS, Stifel, TD Cowen, and Cantor Fitzgerald all lifted targets following the July earnings beat, and BTIG initiated with a Buy at $1,210 in mid-July. The consensus mean target of $1,235 implies around 18% upside from the current $1,044 close. The only outlier is Barclays, holding at Equal-Weight with a $1,130 target — a meaningful discount to the bull consensus. The analyst recommendations factor score ranks in the 92nd percentile of the ORTEX universe, the standout reading across all factor dimensions. Valuation remains the clear friction point: a trailing P/E near 58x and EV/EBITDA of 22x leave little margin for error, and the EV/EBIT factor scores in just the 8th percentile. The bull case rests on AI-driven data center demand; the bear case is simply that the premium embedded in the price already reflects it.
Institutional ownership is broad and incremental rather than concentrated or aggressive. BlackRock holds 11.6% of shares and added roughly 313,000 shares in the latest reported period. UBS Asset Management added a more notable 1.38 million shares, a meaningful move for a mid-sized holder. The insider picture is less encouraging at the margin: net insider activity over the past 90 days reflects around $11.5 million in net selling, with the Lead Independent Director and Chief Legal Officer both making sales in August. None of the individual trades are large relative to the company's size, and most carry low significance scores — routine plan-driven sales remain the most likely explanation — but the absence of any buying into the recent dip is worth noting.
The next earnings date lands October 28. The most recent print in late July produced a mild 1.2% one-day gain and a 2.1% five-day gain. Closest peer DLR fell 2.7% on the week and IRM dropped 3.8%, suggesting the sector-wide softness in recent days is broader than any Equinix-specific story. The gap between the analyst consensus target and the current price — roughly 18% — is the key number to watch as macro rate expectations and AI infrastructure spending data evolve into Q4.
See the live data behind this article on ORTEX.
Open EQIX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
